Update on the management of inflammatory bowel disease: specific role of adalimumab

Luisa Guidi, Daniela Pugliese, Alessandro Armuzzi, Luisa Guidi, Daniela Pugliese, Alessandro Armuzzi

Abstract

Anti-tumor necrosis factor alpha (TNF-α) medications are a class of biologics employed in the treatment of patients with inflammatory bowel disease (IBD). Adalimumab is the first fully human monoclonal immunoglobulin directed against TNF-α, which binds with high affinity and specificity to membrane and soluble TNF. Adalimumab administered subcutaneously has demonstrated efficacy in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and severe chronic psoriasis. Studies have shown that adalimumab is effective for inducing and maintaining remission of moderate-to-severe active Crohn's disease (CD) patients at an induction dose of 160/80 mg (week 0 and 2) and at a maintenance dose of 40 mg every other week. The efficacy of adalimumab as a second-line therapy has also been documented for patients with loss of response or intolerance to infliximab. Adalimumab is also superior to placebo for inducing and maintaining complete perianal fistula closure. It also seems effective for reducing extraintestinal manifestations. The safety profile is similar to that of other anti-TNF therapy in CD patients, with lower immunogenicity and rate of adverse injection reactions than infliximab. Adalimumab is not approved for the treatment of ulcerative colitis (UC). Recently, however, the results of the first randomized, controlled trial on adalimumab for UC showed that adalimumab at 160/80 mg induction dose was safe and effective for inducing remission and clinical response after 8 weeks in patients with moderately-to-severely active UC failing treatment with corticosteroids and/or immunosuppressants. More data are necessary to clarify the therapeutic role of adalimumab in UC. This review of the literature summarizes available data on the efficacy and safety profile adalimumab in patients with IBD.

Keywords: Crohn’s disease; adalimumab; anti-TNF-α; ulcerative colitis.

References

    1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–1640.
    1. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidenced-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.
    1. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483.
    1. Travis SP, Stange EF, Lemann L, et al. European evidenced-based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis. 2008;2:24–62.
    1. Kornbluth A, Sachar D, et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
    1. HUMIRA® Product monograph. Abbott Laboratories; Abbott Park, IL:
    1. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
    1. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.
    1. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
    1. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135:1493–1499.
    1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am J Gastroenterol. 2009;104:1170–1179.
    1. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease:clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17:141–151.
    1. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31:1296–1309.
    1. Lofberg R, Louis E, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CARE. Inflamm Bowel Dis. 2011 [Epub ahead of print].
    1. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for Adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106:674–684.
    1. Colombel JF, Schwarts DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–948.
    1. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228–1239.
    1. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
    1. Panaccione R, Sandborn WJ, D’Haens G, et al. Adalimumab maintains long-term remission in moderately to severely active Crohn’s disease after infliximab failure: 1-year follow-up of GAIN trial. [abstract] Gastroenterology. 2008;134:A133.
    1. Ma C, Panaccione R, Heitman SJ, et al. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther. 2009;15(30):977–986.
    1. Colombel JF, Rutgeerts P, Sandborn WJ. Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: results from EXTEND [abstract] J Crohns Colitis. 2010;4:S10.
    1. Colombel JF, Rutgeerts P, Sandborn WJ. Deep remission predicts long-term outcomes for Adalimumab-treated patients with Crohn’s disease: data from EXTEND [abstract] Gut. 2010;59(Suppl 3):A80.
    1. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric crohn’s disease. Am J Gastroenterol. 2009;104:3042–3049.
    1. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:946–953.
    1. Hyams JS, Griffiths AM, Markowitz J, et al. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn’s disease in children [abstract] Gastroenterology. 2011;140(Suppl 1):S90.
    1. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328–2332.
    1. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28:966–972.
    1. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302–1307.
    1. Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32:522–528.
    1. Taxonera C, Estellés J, Blanco I, et al. Adalimumab for ulcerative colitis patients previously treated with infliximab: outcomes at short and long term and predictors of response. Aliment Pharmacol Ther. 2011;33:340–348.
    1. Hudis N, Rajca B, Polyak S, et al. The outcome of active ulcerative colitis treated with adalimumab [abstract] Gastroenterology. 2009;136:A661.
    1. García-Bosch O, Aceituno M, Perez J, et al. Efficacy of adalimumab in the treatment of ulcerative colitis [abstract] J Crohns Colitis. 2010;4:S55.
    1. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
    1. Reinisch W, Sandborn WJ, Kumar A, et al. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosoppresants [abstract] J Crohns Colitis. 2011;5:S10.
    1. Sandborn WJ, Van Assche G, Thakkar RB, et al. Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis [abstract] J Crohns Colitis. 2011;5:S87.
    1. Sandborn WJ, Van Assche GA, Reinisch W, et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis [abstract] Gastroenterology. 2011;140(5 Suppl 1):S123–S124.
    1. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1308–1319.
    1. Shale MJ, Seow CH, Coffin S, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20–34.
    1. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti–tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.
    1. Fiorino G, Allez M, Malesci A, et al. Review article: TNFα induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921–927.
    1. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–1640.
    1. Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero [abstract] Gastroenterology. 2011;140(5 Suppl 1):S61–S62.
    1. Johnson DL, Jones KL, Chambers CD, et al. Pregnancy outcome in women exposed to adalimumab: the OTIS autoimmune disease in pregnancy project [abstract] Gastroenterology. 2009;136(5 Suppl 1):A27.
    1. Marchioni RM, Kerner C, Lichtenstein GR. Anti-TNF therapy and fetal risk: a systematic review of the literature [abstract] Gastroenterology. 2011;140(5 Suppl 1):S772.
    1. Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475–476.
    1. D’Haens G, Baert F, Van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667.
    1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
    1. van der Valk ME, van Oijen MG, Siersema PD, et al. Crohn’s disease patients treated with adalimumab benefit from co-treatment with immunomodulators: results from a nationwide study in the Netherlands [abstract] Gastroenterology. 2011;140(5 Suppl 1):S264.

Source: PubMed

3
Abonneren